Barry Conrad It's interesting
85 OhashiR.TamaiI.NezuJi JNikaidoH.HashimotoN.OkuA.et al (2001)
Genetic analyses have demonstrated that MASLD is a heterogeneous disorder driven by multiple molecular mechanisms rather than a single pathogenic pathway
The FDA label for tirzepatide notes that co-administration with a combined oral contraceptive (ethinyl estradiol/norgestimate) resulted in a 55% reduction in ethinyl estradiol Cmax and a 20% reduction in norelgestromin Cmax [3]
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Valero YA, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau SM, Kadia TM, Masarova L, Takahashi K, Andreeff M , Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer MA, Huang X, Garcia-Manero G